Recruiting

Home Blood Transfusion

Sponsor:

Thomas Jefferson University

Code:

NCT07121140

Conditions

Hematologic Malignancy

Myelodysplastic Syndromes

Acute Myeloid Leukemia

Transfusion Dependent Cytopenias

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Home Blood Transfusion

Study Details

Brief summary:

This is a pilot single arm study to evaluate the feasibility and acceptability of a home blood transfusion program. Patients will be enrolled with hematologic malignancies and other bone marrow failure syndromes who are transfusion dependent and interested in a home blood transfusion program. Participants enrolled in the study will receive 1-5 units of blood products at home. Data on barriers to administration will be recorded. Surveys and qualitative interviews will be completed to better understand acceptability of the program.

Conditions

Hematologic Malignancy

Myelodysplastic Syndromes

Acute Myeloid Leukemia

Transfusion Dependent Cytopenias

Study ID

NCT07121140

Start date

Jun 3, 2025

Status verified date

Dec, 2025

Completion date

Jun, 2027

Anticipated

Primary completion date

Jun, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Individuals must meet all of the following inclusion criteria in order to be eligible to participate in the study:
  • Provide signed and dated informed consent form Willing to comply with all study procedures and be available for the duration of the study
  • Male or female, over the age of 18
  • Must meet definition of transfusion dependence (require at least 2 blood product transfusions over a 28-day period)
  • Receive their cancer care at SKCCC
  • Have a history of blood product transfusions and NO history of transfusion reactions,
  • Live within a 30-mile range of the Center City SKCCC location.
  • Must be willing to allow people into the home

Exclusion Criteria:

  • An individual who meets any of the following criteria will be excluded from participation in this study:
  • Patients who have a history of a transfusion reaction
  • Heart failure as defined by AHA stage C or NYHA Class II-IV
  • Non-English or Spanish speaking
  • Are unhoused
  • Are incarcerated
  • Have poor venous access
  • Diagnosis of Solid Tumor malignancy
  • Women who are pregnant

Study Design

Enrollment

30 participants

Anticipated

Intervention Model

Single group

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: Experimental - Home Blood Transfusion

Participants will receive 1-2 blood products transfused in the home each week for a total of 5 transfusions. Participants with known RBC antibodies will only be eligible to receive platelet transfusions at home. Research nurse comes to home early to draw CBC and Type and Screen. Infusion nurse delivers blood products to home. Blood product administered. Assess vital signs following administration of blood products. Perform feasibility, acceptability, appropriateness questionnaires. Complete qualitative semi-structured interviews.

Interventions

Home Blood Transfusion

Participants will be provided with transfusion of blood products, specifically red blood cells and platelets, in the home setting.

Primary outcome measure

  • Feasibility of a home blood transfusion program utilizing the RE-AIM framework [ Time Frame: 5 weeks ]
  • Acceptability of a home blood transfusion program utilizing the RE-AIM framework [ Time Frame: 5 weeks ]

Central Contacts and Locations

Central contacts

Adam Binder, MD

215-955-8874Adam.Binder@jefferson.edu

Locations

Thomas Jefferson University Hospital

Recruiting

Philadelphia, Pennsylvania, United States, 19107

Contacts

Adam Binder, MD

215-955-8874adam.binder@jefferson.edu

More Information

Sponsor

Thomas Jefferson University

Last update posted

Dec 16, 2025

Last verified

Dec, 2025

Keywords

  • home blood transfusions
  • blood transfusions
  • RE-AIM
  • Supportive Care

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Thomas Jefferson University on 2025-12-16.